CN105358549A - 新喹唑啉衍生物 - Google Patents
新喹唑啉衍生物 Download PDFInfo
- Publication number
- CN105358549A CN105358549A CN201480029864.4A CN201480029864A CN105358549A CN 105358549 A CN105358549 A CN 105358549A CN 201480029864 A CN201480029864 A CN 201480029864A CN 105358549 A CN105358549 A CN 105358549A
- Authority
- CN
- China
- Prior art keywords
- compound
- substituent
- cell
- group
- wnt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(C)[Si](C)(C)*[C@](CC1)CC[C@]1OS(C)(=*)=O Chemical compound CC(C)(C)[Si](C)(C)*[C@](CC1)CC[C@]1OS(C)(=*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
基因名称 | 基因表达分析 |
AXIN2 | Hs00610344_m1 |
MYC(c–MYC) | Hs00153408_m1 |
ACBT(β-肌动蛋白) | Hs99999903_m1 |
一抗(第一抗体)(稀释浓度) | 二抗(第二抗体)(稀释浓度) | |
1 | 抗AXIN2兔抗体(1/1000) | 抗兔IgG山羊抗体(1/5000) |
2 | 抗c-MYC兔抗体(1/1000) | 抗兔IgG山羊抗体(1/5000) |
3 | 抗β肌动蛋白小鼠抗体(1/10000) | 的抗小鼠IgG山羊抗体(1/5000) |
Claims (5)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013253222 | 2013-12-06 | ||
JP2013-253222 | 2013-12-06 | ||
PCT/JP2014/082300 WO2015083833A1 (ja) | 2013-12-06 | 2014-12-05 | 新規キナゾリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105358549A true CN105358549A (zh) | 2016-02-24 |
CN105358549B CN105358549B (zh) | 2019-09-20 |
Family
ID=53273579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480029864.4A Active CN105358549B (zh) | 2013-12-06 | 2014-12-05 | 喹唑啉衍生物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9682961B2 (zh) |
EP (1) | EP3078660B1 (zh) |
JP (1) | JP6492012B2 (zh) |
KR (1) | KR102338568B1 (zh) |
CN (1) | CN105358549B (zh) |
ES (1) | ES2924480T3 (zh) |
WO (1) | WO2015083833A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105755142A (zh) * | 2016-04-22 | 2016-07-13 | 同济大学苏州研究院 | 一种用于检测人源性axin2基因表达水平的引物探针组合及其应用 |
CN107021960A (zh) * | 2017-06-10 | 2017-08-08 | 曹艳 | 一种治疗恶性肿瘤的药物 |
CN107033138A (zh) * | 2017-06-10 | 2017-08-11 | 曹艳 | 一种治疗恶性肿瘤的药物 |
CN107226815A (zh) * | 2017-06-22 | 2017-10-03 | 曹艳 | 喹唑啉类化合物及其在抗肿瘤药物中的应用 |
WO2022089398A1 (zh) * | 2020-10-28 | 2022-05-05 | 杭州阿诺生物医药科技有限公司 | 一种高活性的hpk1激酶抑制剂 |
WO2023161844A1 (zh) * | 2022-02-23 | 2023-08-31 | 智宠制药(北京)有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY37907A (es) * | 2017-09-29 | 2019-04-30 | Bayer Ag | 3-fenilquinazolin-4 (3h)-onas sustituidas y sus usos |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101454294A (zh) * | 2006-04-06 | 2009-06-10 | 诺华公司 | 用于pdk1抑制的喹唑啉 |
WO2012136492A1 (en) * | 2011-04-04 | 2012-10-11 | Siena Biotech S.P.A. | Wnt pathway antagonists |
KR20130084474A (ko) * | 2012-01-17 | 2013-07-25 | 한국과학기술연구원 | 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535393A (ja) * | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | 2-アミノキナゾリン誘導体 |
KR20130141500A (ko) | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
WO2012088712A1 (en) * | 2010-12-31 | 2012-07-05 | Curegenix Inc. | Compound as wnt signaling inhibitor, composition, and use thereof |
-
2014
- 2014-12-05 KR KR1020157033989A patent/KR102338568B1/ko active IP Right Grant
- 2014-12-05 JP JP2015551587A patent/JP6492012B2/ja active Active
- 2014-12-05 ES ES14868296T patent/ES2924480T3/es active Active
- 2014-12-05 CN CN201480029864.4A patent/CN105358549B/zh active Active
- 2014-12-05 US US14/890,868 patent/US9682961B2/en active Active
- 2014-12-05 WO PCT/JP2014/082300 patent/WO2015083833A1/ja active Application Filing
- 2014-12-05 EP EP14868296.6A patent/EP3078660B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101454294A (zh) * | 2006-04-06 | 2009-06-10 | 诺华公司 | 用于pdk1抑制的喹唑啉 |
WO2012136492A1 (en) * | 2011-04-04 | 2012-10-11 | Siena Biotech S.P.A. | Wnt pathway antagonists |
KR20130084474A (ko) * | 2012-01-17 | 2013-07-25 | 한국과학기술연구원 | 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105755142A (zh) * | 2016-04-22 | 2016-07-13 | 同济大学苏州研究院 | 一种用于检测人源性axin2基因表达水平的引物探针组合及其应用 |
CN107021960A (zh) * | 2017-06-10 | 2017-08-08 | 曹艳 | 一种治疗恶性肿瘤的药物 |
CN107033138A (zh) * | 2017-06-10 | 2017-08-11 | 曹艳 | 一种治疗恶性肿瘤的药物 |
CN107033138B (zh) * | 2017-06-10 | 2018-06-08 | 徐晓东 | 一种治疗恶性肿瘤的药物 |
CN107226815A (zh) * | 2017-06-22 | 2017-10-03 | 曹艳 | 喹唑啉类化合物及其在抗肿瘤药物中的应用 |
CN107226815B (zh) * | 2017-06-22 | 2018-07-31 | 徐州市第一人民医院 | 喹唑啉类化合物及其在抗肿瘤药物中的应用 |
WO2022089398A1 (zh) * | 2020-10-28 | 2022-05-05 | 杭州阿诺生物医药科技有限公司 | 一种高活性的hpk1激酶抑制剂 |
WO2023161844A1 (zh) * | 2022-02-23 | 2023-08-31 | 智宠制药(北京)有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2015083833A1 (ja) | 2015-06-11 |
CN105358549B (zh) | 2019-09-20 |
US9682961B2 (en) | 2017-06-20 |
EP3078660B1 (en) | 2022-07-13 |
JP6492012B2 (ja) | 2019-03-27 |
US20160264555A1 (en) | 2016-09-15 |
ES2924480T3 (es) | 2022-10-07 |
EP3078660A1 (en) | 2016-10-12 |
EP3078660A4 (en) | 2017-05-17 |
KR102338568B1 (ko) | 2021-12-13 |
JPWO2015083833A1 (ja) | 2017-03-16 |
KR20160093543A (ko) | 2016-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105358549A (zh) | 新喹唑啉衍生物 | |
JP6887996B2 (ja) | Tead転写因子自己パルミトイル化阻害剤 | |
ES2750199T3 (es) | Métodos para tratar el cáncer | |
US9334267B2 (en) | RAF inhibitor compounds | |
ES2696700T3 (es) | Derivado de 2,3-dihidro-isoindol-1-on como supresor de quinasa BTK y composición farmacéutica que incluye el mismo | |
Liu et al. | Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents | |
JP6333280B2 (ja) | グルタミナーゼ阻害剤およびその使用方法 | |
BR102015027413A2 (pt) | métodos para tratar infecções pelo vírus filoviridae | |
WO2020163248A1 (en) | Methods and compositions for modulating splicing | |
EP2925318A1 (en) | Treatment of cancer with heterocyclic inhibitors of glutaminase | |
CN104302635A (zh) | 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用 | |
BRPI0615968B1 (pt) | Uso de um composto, composto e composição farmacêutica | |
US20060264439A1 (en) | Inhibitors of polo-like kinase-1 | |
TW202126307A (zh) | 治療性共軛物 | |
CA2619459A1 (en) | Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | |
CN107200716B (zh) | 苯并噁嗪类化合物及其制备方法与应用 | |
ITRM20130366A1 (it) | Multitarget hedgehog pathway inhibitors and uses thereof | |
CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
ES2833473T3 (es) | Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos | |
ES2881960T3 (es) | Inhibidores de proteina quinasa | |
US20160052937A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine compound | |
CN107056754A (zh) | 内嵌脲类结构的wnt通路抑制剂 | |
WO2018145217A1 (en) | Human ets-related gene (erg) compounds as therapeutics and methods for their use | |
KR101713678B1 (ko) | 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물 | |
CN116332908A (zh) | 一种shp2变构抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210805 Address after: Kanagawa, Japan Patentee after: Japan myc gene regulated cancer treatment (Co.,Ltd.) Address before: Tokyo Patentee before: Yamata Teruji Effective date of registration: 20210805 Address after: Tokyo Patentee after: Yamata Teruji Address before: Tokyo Patentee before: National Cancer Center Effective date of registration: 20210805 Address after: Tokyo Patentee after: National Cancer Center Address before: Japan Hyogo Prefecture Patentee before: CARNA BIOSCIENCES, Inc. Patentee before: National Cancer Center |
|
TR01 | Transfer of patent right |